Li Kang Biomedical Co Ltd (6242) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.007x

Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.95 Million ≈ $-187.52K USD) by net assets (NT$843.61 Million ≈ $26.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Li Kang Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Li Kang Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Li Kang Biomedical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Li Kang Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
LAVA THERAP. B.V. EO-12 F:4PKB	N/A
Watos Corea Co. Ltd KQ:079000	0.002x
Uniti SA PA:ALUNT	-0.053x
enX Group Ltd JSE:ENX	0.059x
Kafein Yazilim IS:KFEIN	0.024x
Ascent Solar Technologies, Inc. Common Stock NASDAQ:ASTI	-0.541x
Jinli Group Holdings Ltd TW:8429	0.001x
Covalon Technologies Ltd. V:COV	-0.022x

Annual Cash Flow Conversion Efficiency for Li Kang Biomedical Co Ltd (2002–2024)

The table below shows the annual cash flow conversion efficiency of Li Kang Biomedical Co Ltd from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see 6242 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$855.68 Million ≈ $26.96 Million	NT$65.38 Million ≈ $2.06 Million	0.076x	-50.24%
2023-12-31	NT$630.03 Million ≈ $19.85 Million	NT$96.74 Million ≈ $3.05 Million	0.154x	-44.32%
2022-12-31	NT$570.14 Million ≈ $17.96 Million	NT$157.24 Million ≈ $4.95 Million	0.276x	+124.49%
2021-12-31	NT$492.00 Million ≈ $15.50 Million	NT$60.45 Million ≈ $1.90 Million	0.123x	-23.53%
2020-12-31	NT$508.30 Million ≈ $16.01 Million	NT$81.67 Million ≈ $2.57 Million	0.161x	-16.08%
2019-12-31	NT$483.44 Million ≈ $15.23 Million	NT$92.56 Million ≈ $2.92 Million	0.191x	-15.29%
2018-12-31	NT$466.92 Million ≈ $14.71 Million	NT$105.53 Million ≈ $3.32 Million	0.226x	-8.94%
2017-12-31	NT$445.68 Million ≈ $14.04 Million	NT$110.61 Million ≈ $3.48 Million	0.248x	-23.67%
2016-12-31	NT$340.80 Million ≈ $10.74 Million	NT$110.82 Million ≈ $3.49 Million	0.325x	+42.61%
2015-12-31	NT$280.29 Million ≈ $8.83 Million	NT$63.91 Million ≈ $2.01 Million	0.228x	+24.49%
2014-12-31	NT$227.44 Million ≈ $7.17 Million	NT$41.66 Million ≈ $1.31 Million	0.183x	-18.77%
2009-12-31	NT$128.49 Million ≈ $4.05 Million	NT$28.97 Million ≈ $912.65K	0.225x	+1252.82%
2003-12-31	NT$338.06 Million ≈ $10.65 Million	NT$5.63 Million ≈ $177.50K	0.017x	-87.37%
2002-12-31	NT$347.64 Million ≈ $10.95 Million	NT$45.87 Million ≈ $1.45 Million	0.132x	--

About Li Kang Biomedical Co Ltd

TWO:6242 Taiwan Travel Services

Market Cap

$38.53 Million

NT$1.22 Billion TWD

Market Cap Rank

#22817 Global

#1431 in Taiwan

Share Price

NT$38.45

Change (1 day)

-0.13%

52-Week Range

NT$37.25 - NT$44.15

All Time High

NT$13364.93